Patients with liver cirrhosis and a superimposed acute injury with progressive hyperbilirubinemia have a high mortality. A prospective, controlled study was performed to test whether hyperbilirubinemia, 30-day survival, and encephalopathy would be improved by extracorporeal albumin dialysis (ECAD). Twenty-four patients were studied; 23 patients had cirrhosis; 1 had a prolonged cholestatic drug reaction and was excluded from per protocol (PP) analysis. Patients had a plasma bilirubin greater than 20 mg/dL and had not responded to prior standard medical therapy (SMT). Patients were randomized to receive SMT with ECAD or without (control). ECAD was performed with an extracorporeal device that dialyzes blood in a hollow fiber dialyzer (MW cutoff < 60 kd) against 15% albumin. Albuminbound molecules transfer to dialysate albumin that is regenerated continuously by passage through a charcoal and anion exchange column and a conventional dialyzer. ECAD was associated with improved 30-day survival (PP, 11 of 12 ECAD, 6 of 11 controls; log rank P < .05). Plasma bile acids and bilirubin decreased on average by 43% and 29%, respectively, in the ECAD group after 1 week of treatment, but not in the control group. Renal dysfunction and hepatic encephalopathy improved in the ECAD group, but worsened significantly in the control group. ECAD was safe, with adverse events being rare and identical in both groups. In conclusion, ECAD appears to be effective and safe for the short-term treatment of patients with cirrhosis and superimposed acute injury associated with progressive hyperbilirubinemia and may be useful for increasing survival in such patients awaiting liver transplantation. (HEPATOLOGY 2002;36:949-958.) See Editorials on Pages 1014 and 1017 C urrent therapy of liver failure superimposed on cirrhosis is limited to treatment of the precipitating event and the management of existing and potential complications of liver failure. If the precipitating event can be eliminated, the liver can recover to its previous compensated state. However, there is a critical period of severe danger before hepatic recompensation can occur, or if transplantation is indicated, time may be required to find a suitable donor.
Patients with liver cirrhosis and a superimposed acute injury with progressive hyperbilirubinemia have a high mortality. A prospective, controlled study was performed to test whether hyperbilirubinemia, 30-day survival, and encephalopathy would be improved by extracorporeal albumin dialysis (ECAD). Twenty-four patients were studied; 23 patients had cirrhosis; 1 had a prolonged cholestatic drug reaction and was excluded from per protocol (PP) analysis. Patients had a plasma bilirubin greater than 20 mg/dL and had not responded to prior standard medical therapy (SMT). Patients were randomized to receive SMT with ECAD or without (control). ECAD was performed with an extracorporeal device that dialyzes blood in a hollow fiber dialyzer (MW cutoff < 60 kd) against 15% albumin. Albuminbound molecules transfer to dialysate albumin that is regenerated continuously by passage through a charcoal and anion exchange column and a conventional dialyzer. ECAD was associated with improved 30-day survival (PP, 11 of 12 ECAD, 6 of 11 controls; log rank P < .05). Plasma bile acids and bilirubin decreased on average by 43% and 29%, respectively, in the ECAD group after 1 week of treatment, but not in the control group. Renal dysfunction and hepatic encephalopathy improved in the ECAD group, but worsened significantly in the control group. ECAD was safe, with adverse events being rare and identical in both groups. In conclusion, ECAD appears to be effective and safe for the short-term treatment of patients with cirrhosis and superimposed acute injury associated with progressive hyperbilirubinemia and may be useful for increasing survival in such patients awaiting liver transplantation. ( C urrent therapy of liver failure superimposed on cirrhosis is limited to treatment of the precipitating event and the management of existing and potential complications of liver failure. If the precipitating event can be eliminated, the liver can recover to its previous compensated state. However, there is a critical period of severe danger before hepatic recompensation can occur, or if transplantation is indicated, time may be required to find a suitable donor.
The aim of extracorporeal liver support systems is to provide additional hepatic function during this critical period. 1 Historically, liver support systems were based on the principle of detoxification. 2 Toxic molecules accumulated in the plasma in liver failure were to be removed by passage of blood or plasma over sorbent columns, because most of these molecules are lipophilic and albuminbound. These molecules include bile acids, conjugated bilirubin, aromatic amino acids and their metabolites, medium chain fatty acids, mercaptans, and cytokines. Accumulation of these substances may induce brain, kidney, or macrophage dysfunction; may inhibit the recovery of hepatocytes; or cause reduced vascular tone. [3] [4] [5] [6] [7] [8] [9] [10] However, controlled studies have indicated that hemoperfusion does not increase survival in acute liver failure, 11 because it is not selective and has side effects.
Recently, a new extracorporeal device was introduced 12 that dialyzes whole blood in a hollow fiber dialyzer (MW cutoff Ͻ 60 kd) against 15% human serum albumin.
Albumin-bound molecules transfer to dialysate albumin that is continuously regenerated by passage through a charcoal and anion exchange column to maintain albumin binding sites unoccupied and a conventional dialyzer to remove small water soluble toxins. This system was used previously as an alternative to hemodialysis in hepatorenal syndrome. 13 Here, we report the results of a prospective, controlled, randomized trial using extracorporeal albumin dialysis (ECAD) in patients with cirrhosis who developed a superimposed acute liver injury leading to severe hyperbilirubinemia, a condition associated with a high mortality. 14, 15 
Patients and Methods

Experimental
Design. An open-label, randomized, controlled parallel group design was conducted at the Liver Transplant Centers of the Universities of Essen and Rostock, Germany. After qualifying for the trial, patients were randomized either to standard medical therapy with extracorporeal albumin dialysis (ECAD) or without (control). Randomization was performed by the Biometric Department of the University of Rostock based on the SAS module, using a ratio of 1:1 treatment:control in blocks of 6 patients. A set of blind envelopes were given to both centers. Patients were treated with albumin dialysis (up to 10 treatments) during the first 2 weeks. All patients were followed for 30 days or until death. The protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Medical Ethics Committees of the 2 universities. All subjects (or in some instances, their closest relatives) gave informed consent.
Trial Entry. All patients between 18 and 65 years old presenting with cirrhosis (Child-Turcotte-Pugh Index [CTP], 7 and higher) and a superimposed acute liver injury leading to decompensation and severe hyperbilirubinemia (serum total bilirubin Ͼ 20 mg/dL) were screened. Cirrhosis was determined by clinical diagnosis, biochemistry and biopsy, and/or Doppler ultrasound/ computed tomography scan. If no exclusion criteria were present, patients were enrolled into the prephase of the trial to follow the bilirubin trend as well as to complete assessment of inclusion/exclusion criteria and to prepare logistics for potential ECAD treatment. Therefore, the prephase was allowed to vary between 3 and 5 days until exclusion or randomization occurred. During the prephase, the acuity of the event was determined by the bilirubin trend and analyzing the precipitating event (diagnosis of bleeding, infection and recording history of medication or alcohol intake). The bilirubin trend was assessed by daily measurement and entering the prephase data into Sigmaplot 2000 for Windows, Version 3.0 (SPSS Inc., Chicago, IL) for linear regression analysis. If the slope was negative (Ͻ0), patients were not included. If the slope was positive, patients were randomized if they met all inclusion/exclusion criteria. Exclusion criteria included hepatobiliary obstruction, inability to undergo the extracoporeal treatment because of active bleeding or sepsis causing hemodynamic instability, or comorbid conditions associated with a poor outcome (as necrotic pancreatitis, cancer or cardiopulmonary failure). Also, patients were excluded if they had coma of nonhepatic origin, extensive surgery during the month before admission, or if they were pregnant. Patients with hepatorenal syndrome (type I and type II) as defined by Arroyo et al. 16 were excluded because of a concurrent trial using ECAD for this patient population that has now been published. 13 In both groups, standard medical therapy focused on treating the precipitating event and treatment of clinical problems associated with liver failure. Sources of bleeding were identified and treated. When indicated, proton pump inhibitors or H 2 -blockers were given. Infections were assessed and treated with appropriate antibiotics. Because of the high incidence of infection, steroids were not given as standard treatment for alcohol induced injury. If diuretic-resistant ascites was present, paracentesis was performed with a simultaneous intravenous infusion of 8 g albumin per L of ascitic fluid removed. For encephalopathy, a protein-restricted diet and lactulose were given. Patients with renal failure requiring dialysis received intermittent or continuous (if hemodynamically instable) hemofiltration if they developed anuria, lifethreatening electrolyte disorders, or uremia. If the prothrombin time value (Quick) or antithrombin III value was less than 50%, and active bleeding was present, then appropriate amounts of red blood cells, fresh frozen plasma, or individual clotting factors and antithrombin III (Behring AG, Germany) were given to maintain Quick and antithrombin III activity greater than 50%.
Albumin Dialysis Treatment. The Molecular Adsorbents Recycling System (MARS, Teraklin AG, Rostock, Germany) was used. A description of the device is explained in Fig. 1 The ECAD treatment began within 24 hours after randomization. As determined by daily assessment, ECAD treatment would only be given if bilirubin was greater than 15 mg/dL but was discontinued when the patient reached the end point (bilirubin Ͻ 15 mg/dL for 3 consecutive days off treatment). If bilirubin levels persisted above 15 mg/dL, ECAD treatment was continued daily until the patient had received 10 treatments.
Study End Points and Observations. A decrease in serum bilirubin (morning levels Ͻ 15 mg/dL for 3 consecutive days) was the primary end point of the study. Bilirubin has been shown to be useful in predicting outcomes of patients with cirrhosis. 14, 15 It is part of the CTP Index, the Model for End-Stage Liver Disease Score and the Maddrey's discriminant function formula.
A secondary end point of the trial was in-hospital survival. In addition, patients had daily evaluation of prothrombin time value (Quick), mean arterial pressure, and serum creatinine and bile acids. Patients were evaluated daily for presence of hepatic encephalopathy (HE) grade by the attending physicians who followed the patient during his hospital stay according to the table based on the West Haven Criteria for semiquantitative grading of mental state. 17 Briefly, grade 1 reflects lack of awareness, grade 2 reflects lethargy/apathy, grade 3 reflects somnolence/semistupor, and grade 4 reflects coma. In addition, the patients were evaluated weekly for the presence of ascites. The CTP score was calculated at randomization and weekly based on physical findings, prothrombin time value (Quick), albumin, and bilirubin. 18, 19 The documentation of adverse events followed the general recommendations of clinical safety data management executed by the monitor (IMEREM GmbH, Nurenberg, Germany). For example, the following adverse events were recorded: acute hypotension (mean arterial pressure Ͻ 50 mmHg) requiring medical intervention, worsening of renal function (creatinine Ͼ 1.5 mg/dL) unresponsive to 1.5 L fluid administration, new formation of ascites, worsening of HE as defined by progression to grade 4, new onset of disorientation (in time and/or space) during extracorporeal treatment, coagulopathy as defined by new onset of disorder of prothrom- Blood from the patient is pumped through an albumin impermeable hollow fiber dialyzer (1). The dialysate contains human albumin (15 g/dL), which binds molecules that diffuse through the pores of the membrane (schematic picture). Molecules that are bound to the albumin in the dialysate are removed by passing through a charcoal column (3) and an anion exchange (2) column. The technique (Molecular Adsorption in a Recycling System) is abbreviated as MARS. The albumin solution is also subjected to a conventional single pass dialysis procedure (4) to remove dialyzable ions of low molecular weight. Blood flow and albumin flow were 150 to 250 mL/min, and single pass dialysis flow was 500 mL/min. bin time (Quick Ͻ 70%) or platelets (Ͻ150 ϫ 10 3 /L), gastrointestinal bleedings, or other hemorrhage as defined by the need of procedures and/or transfusion of more than 2 units of blood, anemia as defined by a nonbleeding related drop of hematocrit (Ͻ 20%) requiring more than 2 units of blood, dyspnea as defined by the need for oxygen mask or ventilation, arterial puncture, or fever/sepsis related to the double lumen catheter, and any other deterioration of general clinical condition not covered by the previous definitions and that required procedures.
Data Analysis. Entry biochemical data, the time patients had bilirubin greater than 20 mg/dL before randomization, age, initial HE grade, and CTP score were compared by the Mann-Whitney U test. Additionally, baseline analysis included the incidence of gender, underlying disease, and precipitating event, which were compared in both groups by a 2 procedure. For survival analysis, a log rank test was performed.
The time course of the CTP score, HE grade, serum bilirubin, serum albumin, and prothrombin time value (Quick) were evaluated for changes between baseline and weekly main visits with the signed rank statistic for before/after differences. The same test was used to evaluate changes of bilirubin and bile acids.
The Mann-Whitney U test was used for differences between treatment groups at defined time points (after 1, 2, 3, and 4 weeks). For nonsurvivors, the last available data were entered into analysis. An observed case analysis was performed together with an end point analysis with the Last-Observation-Carried-Forward method.
Adverse events were grouped by those considered related to extracorporeal procedures or those related to cirrhosis. Frequencies were compared by 2 test. Main end point and survival data are presented for intention to treat (ITT) and per protocol (PP) analysis. Unless noted, other results are given for PP analysis.
Results
Patient Selection. Forty-six patients were evaluated for possible entry into the study. In 14 patients, bilirubin decreased during the prephase, precluding their entry into the study. Another 8 patients had the following exclusion criteria: hepatorenal syndrome (n ϭ 4), acute liver failure (n ϭ 1), refractory gastrointestinal bleeding (n ϭ 1), and fungal sepsis with hemodynamic instability (n ϭ 1). One patient declined further study. Twenty-four patients entered the study with 12 being randomized to each group. Table 1 summarizes the etiology of chronic liver disease, the precipitating event, the presence of comorbidity, the length of the prestudy hospitalization period, and the time their bilirubin had been above 20 mg/dL. The median of this time was 10.5 (range, 3 to 72) days because some patients came from referring centers. This time did not exceed 30 days except for one patient in both groups. The final column shows the time to response or death.
Twenty-three patients had cirrhosis, whereas 1 patient's (patient 19) biopsy revealed prolonged cholestatic drug reaction induced by an anabolic agent; therefore, patient 19 was excluded from PP analysis. Of the 23 patients with cirrhosis, 20 had a history of alcohol abuse. Table 2 summarizes patient demographics, laboratory tests, hematologic indices, the time patients had bilirubin greater than 20 mg/dL, stage of HE, and calculated CTP score at admission as well as at study entry. There were no significant differences between the ECAD group and the control group.
There were no differences in the incidence of cause of liver disease or the precipitating events. Specifically, the incidence of patients in whom the recent intake of alcohol contributed to the acute deterioration was comparable (7 of 12 in the ECAD and 9 of 12 in the control group). Maddrey's discriminant function was calculated with baseline prothrombin time. The Model for End-Stage Liver Disease Score was calculated by using baseline creatinine, total bilirubin, and INR (prothrombin time/ normal prothrombin time) ISI (International Sensitivity Index). There was no significant difference in the Model for End-Stage Liver Disease (calculated for all patients) or the Maddrey's discriminant function (neither if applied to the 20 patients who had alcohol [ETOH] history nor if applied to the 16 patients in whom the recent alcohol intake might have contributed to the acute deterioration).
Standard medical therapy was not different in the 2 groups (neither in ITT nor in PP analysis; data given for PP analysis). There were no significant differences in the use of antibiotics, proton pump inhibitors, or H 2 blockers.
Further treatment variables examined included the use of steroids (1 of 12 ECAD versus 0 of 11 control, no significant differences), fresh frozen plasma (5 of 12 ECAD patients [median, 0; range, 0 to 18.400 mL] versus 7 of 11 controls [median, 800; range, 0 to 5.800 mL]), and other blood products, specifically albumin (4 of 12 ECAD patients [median, 0; range, 0 to 200 mL] versus 8 of 11 controls [median, 40; range, 0 to 480 mL]). Also, there was no significant difference in the administration of paracentesis. In 5 of 12 patients of the ECAD group, 1 to 4 paracentesis (median, 100; range, 100 to 2.000 mL) were perfomed, whereas in 6 of 11 control patients, 1 to 2 paracentesis (median, 300; range, 100 to 2.900 mL) were performed.
There was no difference in intensive care or pressure support given to the patients. ECAD was performed in †Death (nonsurvivors who died on day indicated). ‡Partial SBR, partial small bowel resection. §Patient dropped out before study end point. Due to no laboratory analysis after discharge, for conventional evaluation, the patient was considered to be a nonresponder. the hospital's dialysis center, and patients returned to their wards after treatment. Medicine subject to extracorporeal removal was administered immediately after the treatment. None of the patients were on ventilation at study entry; however, because of deterioration, 1 of 12 ECAD patients and 3 of 11 control patients needed ventilator support later.
Of the 24 patients who entered the study, 15 completed the 30 days. Seven patients died. One patient discontinued ECAD because of catheter-related problems and 1 patient chose to withdraw from the study after his tenth ECAD treatment because she improved and wanted to be discharged, declining further follow up. In the original protocol, it had been planned to study 48 patients and to perform an interim analysis after half of the patients had reached their end point.
All 24 patients were enrolled into ITT analysis. As biopsy revealed diagnosis of prolonged drug-induced cholestasis rather than cirrhosis in patient 19 a separate PP analysis was performed excluding this patient.
Efficacy. At 30 days, 1 of 12 patients receiving the ECAD treatment had died compared to 6 of 12 (6 of 11 PP) patients in the control group (log rank ITT and PP analysis; P Ͻ .05). Thirty-day mortality was 50% (54.4% NOTE. The table compares baseline characteristics of prognostic importance of both groups (ECAD, n ϭ 12; control, n ϭ 11; patient 19 not included). Data are in median values and ranges (minimum-maximum). The last column shows comparison with the Mann-Whitney U Test (except for gender, which was compared using the 2 test).
Abbreviations: AST, aspartate aminotransferase; ALT, alamine aminotransferase; GGT, gamma glutamyl transferase; AP, alkaline phosphatase. *Grade detected by the method described in Atterbury et al. 17 †Child-Turcotte-Pugh Score as detected in accordance to Child 18 and Pugh. 19 ‡All patients presenting with hepatorenal syndrome (type I or II) were excluded. Patients with elevated creatinine levels usually presented with dehydration and responded well after administration of fluids.
PP) in the control group, whereas it was 8.3% in the ECAD group (ITT analysis, P ϭ .069; PP analysis, P ϭ .027 in the 2-tailed Fisher's exact test).
The Kaplan-Meier survival curves are shown in Fig. 2 . After inclusion into the trial, the patient in the ECAD group who died developed fungal sepsis from a local fungal infection present at entry to the trial. Deaths in the treatment group were caused by multiorgan failure after the development of renal dysfunction. This was pre-existent in 1 of the 6 subjects who died in the control group and developed in the 5 others who died during the study.
No statistically significant differences were found for creatinine, prothrombin time, bilirubin, Model for EndStage Liver Disease, Maddrey's discriminant function, albumin, HE, CTP, and all other baseline parameters by retrospective analysis for survivors and nonsurvivors at study entry.
The interim analysis disclosed the greater mortality in the control group. The Ethics Committee recommended to stop the study and design a new protocol that would provide patients who deteriorate a chance to cross over.
After 6 months, 6 of 12 (50%) ECAD patients were still alive (1 received a transplant 1 month after study completion) whereas 4 of 11 (50%) control patients were still alive (1 received a transplant 3 days after study completion). None of the patients had received additional ECAD treatments after the completion of the trial.
The primary end point of bilirubin less than 15 mg/dL for 3 consecutive days was reached in 5 of 12 patients in the ECAD group and in 2 of 12 patients (2 of 11 PP) in the control group. The median time to reach this end point was shorter in the ECAD group (3, 6, 6, 8, and 21 days) than in the control group (17 and 24 days). However, this difference was not significant, presumably because of the small number of patients that were studied when the Ethics Committee stopped the trial.
Serum bilirubin and bile acid levels as markers for albumin-bound molecules were decreased significantly on the consecutive day after ECAD treatment. Bilirubin decreased from 25 (13 to 50) mg/dL to 23 (13 to 50) mg/dL (P Ͻ .005) and bile acids from 106 (47 to 404) mol/L to 84 (47 to 404) mol/L (P Ͻ .001). The individual time course of bilirubin levels are shown in Fig. 3 ; mean values of bile acids at baseline and changes from baseline during the study are summarized in Table 4 . Values for both of these organic anions remained unchanged in the control group.
Mean arterial pressure increased significantly in the treatment group, but decreased in the control group. Worsening of renal function occurred in 1 of 12 patients Fig. 3 . Trend of serum (total) bilirubin for every patient. Values for the control group are shown in the upper panel and those for the ECAD group in the lower panel. Treatments are indicated by dots. The reduction of serum bilirubin in the ECAD group within 1 and 2 weeks was statistically significant (signed rank statistic for pre/post-differences). If the end point (serum bilirubin less than 15 mg/dL for 3 days) was reached, it is indicated by an upward-pointing triangle. Death is indicated by a downward-pointing triangle. in the ECAD group, but in 7 of 12 (7 of 11 PP) patients in the control group, showing a significant difference (P Ͻ .05 in the 2 test in ITT and PP analysis).
HE improved significantly in the ECAD group, but worsened in the control group (see Fig. 4 ). Serum albumin levels increased in the ECAD group from 32.9 (21.9 to 42.3) at baseline to 38.1 (23.2 to 46.2) at study end (median in g/L, range in parentheses). There was only a slight increase in the control group from 28.8 (18.8 to 44.6) at study entry to 30 (15.5 to 37.5) at study end (median in g/L, range in parenthesis). In summary, the change from baseline albumin in the ECAD group over the study was ϩ5.3 (Ϫ4.2 to ϩ13.7), whereas it was 0 (Ϫ7 to ϩ9.5) in the control group (median change in g/L, range in parenthesis). These changes did not differ significantly between the 2 groups.
Prothrombin time value (Quick) did not change significantly neither in the ECAD group (from 51 [16 to 76]% at study entry to 42 [25 to 100]% at study end) nor in the control group (from 47 [31 to 87]% at study entry to 43 [19 to 70]% at study end), data given in median change in %, range in parentheses. Table  2 ), total serum bile acids in mol/L, mean arterial pressure in mm Hg, and serum creatinine in ECAD versus Control patients. Week 2 was chosen because it reflects the timepoint in which all ECAD treatments were given and the week 4 timepoint because it was the end of the study. Significant changes compared with baseline within both groups (signed rank statistic for pre/post-differences) are indicated by asterisk (P Ͻ .05), and significant differences between both groups (Mann-Whitney U Test) are shown in the table.
Progression of ascites did not appear in any of the ECAD group but in 1 of 12 (1 of 11 PP) patients in the control group. The ECAD group had improvement in encephalopathy and albumin, and no progression of ascites. This resulted in a significantly lower CTP score as compared with the control group (see Table 4 ).
Safety. Adverse events were assigned to either extracorporeal treatment (ECAD in the treatment group, routine dialysis in the control group) or to the liver disease per se. The ECAD procedure was well tolerated in all patients, but 2 patients had fever/sepsis possibly related to the presence of a catheter. Regarding complications of liver cirrhosis, the ECAD group showed less encephalopathy, less renal deterioration, and less episodes of electrolyte imbalance. One patient in the ECAD group spent 4 days in the intensive care unit, whereas 3 patients in the control group spent 4, 6, and 9 days in the intensive care unit at the end of the study period.
Discussion
Our report summarizes the first controlled trial of extracorpeal albumin dialysis in liver failure and progressive hyperbilirubinemia superimposed on cirrhosis. Use of the albumin dialysis procedure was associated with decreased 30-day mortality and improvement of hepatic encephalopathy, arterial blood pressure, renal function, and hyperbilirubinemia. Adverse effects were similar in the ECAD and control groups, suggesting the procedure is safe. The study was small, but we were advised to stop the study at its halfway point because of the favorable effects of albumin dialysis treatment on mortality.
The poor survival in the control group is in agreement with literature estimates of the prognosis of such patients. 14, 15 Patients died of multiorgan failure after progressing to renal failure and hepatic coma. Molecules that accumulate in liver failure and hyperbilirubinemia are known to induce renal dysfunction 4, 5 and albumin dialysis prolonged survival in hepatorenal syndrome in another controlled study. 13 The improvement in HE by extracorpeal albumin dialysis is likely the result of reduction of molecules involved in the pathogenesis of HE such as ammonia, middlechain fatty acids, tryptophane, and its metabolites and others. 3 In addition, the removal of cytokines affecting the function of the blood-brain barrier may play a role. A possible defect in the study was that the attending physician was not blinded to the treatment of the patient when evaluating the encephalopathy, which may have caused a bias in the evaluation. However, the reported improvement of HE by albumin dialysis is consistent with studies performed by other centers. [20] [21] [22] [23] [24] [25] The higher serum albumin in the ECAD group at study end cannot be explained by improvement of synthesis, because the prothrombin time value (Quick), as another sensitive synthetic parameter, remained statistically unchanged in both groups at study end. However, as the amount of albumin infusion was not different between both groups, this tendency might be a secondary result of different tendencies of intravascular volume status caused by different courses of renal dysfunction and requires further studies.
The increase of arterial pressure is in agreement with 2 previous studies with extracorporeal albumin dialysis that reported evidence for an increase in peripheral vascular resistance. Mechanisms such as the clearance of inflammatory cytokines (e.g., interleukin-6, tumor necrosis factor-␣) might be involved 23 and need to be investigated further.
One aspect to be noted is that the study was composed of heterogeneous patients. Therefore, extensive comparison of both groups with respect to cause of liver disease, precipitating event, prognostic parameters, acuity of the disease, and medical treatment was performed. None of these tests revealed statistically significant differences be- Fig. 4 . Trend of HE in the ECAD and control group (medians). Ranges (min-max) are indicated for each group at each time point. Extracorporeal albumin dialysis was performed during the first 2 weeks, but the improvement in encephalopathy grade persisted throughout the 30 days of the study for the ECAD group. For patients who died, the last observed value was carried forward. Statistical evaluation with the signed rank statistic for pre/post-differences (indicated by asterisk at ranges) indicated that albumin dialysis resulted in a significant improvement of the HE score for the ECAD group at 1 week, whereas HE progressed in the control group significantly during weeks 2, 3, and 4 (indicated by asterisk at changes). At any visit after ECAD treatment, there was a significantly lower degree of HE in the ECAD group compared with the control group (P for Mann-Witney U test indicated).
tween the groups. However, because of the heterogenecity and the small sample size, the data should be supported by further studies.
Another aspect to be noted is that the study was predominantly composed of patients with ETOH history who had acute injury as a result of recent alcohol intake or superimposed infection. Therefore, extrapolation of the findings to other patient populations (i.e., acute viral hepatitis superimposed on postviral cirrhosis) requires confirmation by further studies.
Improvement in long-term outcome of patients with end-stage liver disease with extracorporeal albumin dialysis is not yet known. It has been used to restore the patient to his or her state of hepatic compensation before the insult causing acute decompensation. [20] [21] [22] [23] [24] [25] In conclusion, this small, prospective, controlled trial indicates that extracorporeal albumin dialysis is effective for short-term survival and improves the clinical condition of patients with cirrhosis and superimposed acute injury that results into progressive hyperbilirubinemia. The procedure appears to be safe and well tolerated. Further trials are in progress that will test the validity of our findings.
